Literature DB >> 22205675

The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry.

Stella Hughes1, Timothy Spelman, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Francois Grand'maison, Pierre Duquette, Marc Girard, Pierre Grammond, Celia Oreja-Guevara, Raymond Hupperts, Cavit Boz, Roberto Bergamaschi, Giorgio Giuliani, Maria Edite Rio, Jeannette Lechner-Scott, Vincent van Pesch, Gerardo Iuliano, Marcela Fiol, Freek Verheul, Michael Barnett, Mark Slee, Joseph Herbert, Ilya Kister, Norbert Vella, Fraser Moore, Tatjana Petkovska-Boskova, Vahid Shaygannejad, Vilija Jokubaitis, Gavin McDonnell, Stanley Hawkins, Frank Kee, Orla Gray, Helmut Butzkueven.   

Abstract

BACKGROUND: The Expanded Disability Status Scale (EDSS) is widely used to rate multiple sclerosis (MS) disability, but lack of disease duration information limits utility in assessing severity. EDSS ranking at specific disease durations was used to devise the MS Severity Score, which is gaining popularity for predicting outcomes. As this requires validation in longitudinal cohorts, we aimed to assess the utility of EDSS ranking as a predictor of 5-year outcome in the MSBase Registry.
METHODS: Rank stability of EDSS over time was examined in the MSBase Registry, a large multicentre MS cohort. Scores were ranked for 5-year intervals, and correlation of rank across intervals was assessed using Spearman's rank correlation. EDSS progression outcomes at 10 years were disaggregated by 5-year EDSS scores.
RESULTS: Correlation coefficients for EDSS rank over 5-year intervals increased with MS duration: years 1-6=0.55, years 4-9=0.74, years 7-12=0.80 and years 10-15=0.83. EDSS progression risk at 10 years after onset was highly dependent on EDSS at 5 years; one-point progression risk was greater for EDSS score of >2 than ≤2. Two-point progression was uncommon for EDSS score of <2 and more common at EDSS score of 4.
CONCLUSIONS: EDSS rank stability increases with disease duration, probably due to reduced relapses and less random variation in later disease. After 4 years duration, EDSS rank was highly predictive of EDSS rank 5 years later. Risk of progression by 10 years was highly dependent on EDSS score at 5 years duration. We confirm the utility of EDSS ranking to predict 5-year outcome in individuals 4 years after disease onset.

Entities:  

Mesh:

Year:  2011        PMID: 22205675     DOI: 10.1136/jnnp-2011-301051

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  9 in total

Review 1.  ["Time is brain" in relapsing remitting multiple sclerosis. Current treatment concepts in immunotherapy].

Authors:  R Linker; B-A Kallmann; C Kleinschnitz; P Rieckmann; M Mäurer; S Schwab
Journal:  Nervenarzt       Date:  2015-12       Impact factor: 1.214

2.  Perivascular space is associated with brain atrophy in patients with multiple sclerosis.

Authors:  Xue-Yu Liu; Gai-Ying Ma; Shi Wang; Qian Gao; Cong Guo; Qiao Wei; Xuan Zhou; Li-Ping Chen
Journal:  Quant Imaging Med Surg       Date:  2022-02

3.  Quantification of multiple-sclerosis-related brain atrophy in two heterogeneous MRI datasets using mixed-effects modeling.

Authors:  Blake C Jones; Govind Nair; Colin D Shea; Ciprian M Crainiceanu; Irene C M Cortese; Daniel S Reich
Journal:  Neuroimage Clin       Date:  2013-08-13       Impact factor: 4.881

4.  A longitudinal model for disease progression was developed and applied to multiple sclerosis.

Authors:  Michael Lawton; Kate Tilling; Neil Robertson; Helen Tremlett; Feng Zhu; Katharine Harding; Joel Oger; Yoav Ben-Shlomo
Journal:  J Clin Epidemiol       Date:  2015-05-14       Impact factor: 6.437

Review 5.  Management of multiple sclerosis patients in central European countries: current needs and potential solutions.

Authors:  Thomas Berger; Monika Adamczyk-Sowa; Tünde Csépány; Franz Fazekas; Tanja Hojs Fabjan; Dana Horáková; Zsolt Illes; Eleonóra Klimová; Fritz Leutmezer; Konrad Rejdak; Csilla Rozsa; Saša Šega Jazbec; Jarmila Szilasiová; Peter Turčáni; Marta Vachová; László Vécsei; Eva Havrdová
Journal:  Ther Adv Neurol Disord       Date:  2018-02-22       Impact factor: 6.570

6.  Comparison of susceptibility weighted imaging with conventional MRI sequences in multiple sclerosis plaque assessment: A cross-sectional study.

Authors:  Masoud Rabbani; Vahid Shaygannejad; Mahshid Bahrami; Sajad Badiei
Journal:  J Res Med Sci       Date:  2021-12-22       Impact factor: 1.852

7.  Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry.

Authors:  Cecilia Smith Simonsen; Heidi Øyen Flemmen; Line Broch; Cathrine Brunborg; Pål Berg-Hansen; Stine Marit Moen; Elisabeth Gulowsen Celius
Journal:  Front Neurol       Date:  2021-06-17       Impact factor: 4.003

8.  Exploring the predictive value of the evoked potentials score in MS within an appropriate patient population: a hint for an early identification of benign MS?

Authors:  Nicolò Margaritella; Laura Mendozzi; Massimo Garegnani; Raffaello Nemni; Elena Colicino; Elisabetta Gilardi; Luigi Pugnetti
Journal:  BMC Neurol       Date:  2012-08-22       Impact factor: 2.474

9.  Does levetircetam decrease of the rubral tremor in patients with multiple sclerosis.

Authors:  Ahmad Chitsaz; Noushin Mehrbod; Masoud Etemadifar; Mohamadreza Najafi
Journal:  J Res Med Sci       Date:  2013-03       Impact factor: 1.852

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.